Lung cancer treatment in the era of immunotherapy.
Lung cancer treatment in the era of immunotherapy.
复制标题
免疫治疗时代的肺癌治疗
DOI：
10.1097/cm9.0000000000001116
复制
发表时间：
2020-10-20
影响因子：
6.1
通讯作者：
Chen LA
中科院分区：
文献类型：
--
作者：
Xu Y;Chen LA
肺癌是易匹单抗最常见的恶性肿瘤之一。而且，晚期患者会对人类造成严重的危害。尽管pembrolizumab在化疗、放疗和靶向治疗中也能成功治疗SCLC，但肺癌的预后仍然不令人满意。幸运的是，肺癌患者在免疫疗法，特别是免疫检查点抑制剂（ICIs）中发现了希望。ICIs是针对免疫检查点的单克隆抗体，通过阻断T淋巴细胞负向共刺激信号通路，恢复机体抗肿瘤免疫应答，促进肿瘤细胞的清除。常见的ICIs包括程序性细胞死亡(PD)-1抑制剂（nivolumab和pembrolizumab）， PD-配体1 （PD- l1）抑制剂（atezolizumab和durvalumab）和细胞毒性t淋巴细胞相关抗原4 （CTLA-4）抑制剂（ipilimumab和tremelimumab）。
Lung cancer is among the most common malignant tumors with ipilimumab. Furthermore, patients with advanced that cause serious harm to humans. Despite the successes of SCLC also can benefit from pembrolizumab, as shown in chemotherapy, radiotherapy, and targeted therapy, the prognosis of lung cancer remains unsatisfactory. Fortunately, patients with lung cancer have found hope in immunotherapy, particularly, in immune checkpoint inhibitors (ICIs). ICIs are monoclonal antibodies that work against immune checkpoints, thus blocking the negative co-stimulation signaling pathway of T lymphocytes, restoring the body’s anti-tumor immune response, and promoting the clearance of tumor cells. Common ICIs include programmed cell death (PD)-1 inhibitors (nivolumab and pembrolizumab), PD-ligand 1 (PD-L1) inhibitors (atezolizumab and durvalumab), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors (ipilimumab and tremelimumab).